Idarubicin
Idamycin
Near Add Your Location
Accepting patients
A Combination of Cladribine, Idarubicin, Cytarabine (CLIA) and Quizartinib for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS))
- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
Accepting patients
Chemotherapy Plus Venetoclax
Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML
- BCL-2 Inhibitor
- Kinase Inhibitor
- Tyrosine Kinase (TK) Inhibitor
- Phase 2
Accepting patients
Gemtuzumab as Part of Chemotherapy
A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia
- Antibody Drug Conjugate (ADC)
- Hypomethylating Agents (HMA)
- White Blood Cell Stimulant
- CD33
- Phase 2
Accepting patients
Heart Protection w/Dexrazoxane During Chemotherapy
Cardioprotection With Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS), Myeloid Blast Phase of Chronic Myeloid Leukemia (CML), Ph+ AML, and Myeloid Blast Phase of Myeloproliferative Neoplasms
- Chemotherapy
- Phase 2
Accepting patients
Venetoclax w/ Combination Chemotherapy
A Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive AML Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory AML
- BCL-2 Inhibitor
- Chemotherapy
- Phase 1/2
Accepting patients
PVEK (IMGN632)
Phase 1 Study of FLAG-Ida With Pivekimab Sunirine (PVEK [IMGN632]) for Adults With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
- Antibody Drug Conjugate (ADC)
- CD123
- Phase 1
Accepting patients
Decitabine Combination Therapy Pre-ASCT
Sequential Decitabine in Combination With FLAG-Ida Followed Immediately by Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation (DEC-FLAG-Ida/RIC) for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1/2 Study
- Allogeneic Stem Cell Transplant
- Chemotherapy
- Hypomethylating Agents (HMA)
- Phase 1/2
Not yet accepting
Combination Chemotherapy Pre-Allogeneic SCT
Pilot Study of FLAG-Ida Followed Immediately by Reduced-Intensity Allogeneic HCT for Adults Age 60 and Older With Newly Diagnosed Adverse-Risk AML or Other High-Grade Myeloid Neoplasm
- Allogeneic Stem Cell Transplant
- Chemotherapy
- Radiation
- Phase 2
Showing 1-8 of 8